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Implantation of a leadless pacemaker in a pediatric
patient with congenital heart diseaseAnthony C. McCanta, MD, FHRS,*† Gira S. Morchi, MD,*† Froilan Tuozo, NP,*†
Farhouch Berdjis, MD,* Joanne P. Starr, MD,*† Anjan S. Batra, MD, FHRS*†From the *Heart Institute, Children’s Hospital Orange County, Orange, California, and †University of
California Irvine, Pediatric CardioPulmonary Center, Orange, California.Introduction
Patients with congenital heart disease (CHD) and significant
postoperative atrioventricular (AV) nodal injury frequently
require lifelong backup pacing. However, lifelong pacing
in this population is complicated primarily by lead-related is-
sues. Pacing leads in pediatric patients with CHD fail earlier
and at higher rates than leads in adults with structurally
normal hearts for both epicardial and endocardial leads.1 So-
matic growth and the vigorous activity of pediatric patients
lead to higher rates of fracture and dislodgment. Surgical
repair requiring exogenous materials, including bioprosthetic
valves and patches, places transvenous pacing leads in pa-
tients with CHD at higher risk for infection; this necessitates
extraction procedures for lead removal, which carry up to 2%
risk of serious complications, including death.2,3
Transvenous leads carry significant risk of venous
thrombosis and occlusion over the life of pediatric patients
and thus have a profound effect in CHD patients who may
require frequent venous access for interventional cardiac
catheterization procedures, including balloon angioplasty of
pulmonary arteries (PAs) and transcatheter pulmonary
valve implantation. For these reasons, leadless pacing can
be a valuable intervention to minimize the lifelong
complications of epicardial or transvenous pacing in
pediatric patients with CHD.Case report
A 12-year-old, 37-kg girl with a history of repaired tetralogy
of Fallot with pulmonary atresia and postoperative high-
grade heart block status post epicardial pacemaker placement
at 5 months was referred to the pediatric electrophysiology
department for epicardial pacemaker lead fracture. The
patient was asymptomatic, with first-degree heart block andKEYWORDS Congenital heart disease; Leadless pacemaker; Pediatrics;
Tetralogy of Fallot; Transcatheter pacing system
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second-degree type II heart block at night. Based on the
unpredictability of recurrence of postoperative heart block
in patients with CHD4,5 and the continued occasional high-
grade heart block, implantation of a new VVI pacing system
was recommended.
Because the patient had previously undergone 4 sternoto-
mies for surgical repairs, including central shunt placement
and unifocalization of the PAs at age 3 weeks, complete
repair with right ventricle to pulmonary artery (RV-PA)
conduit and closure of ventricular septal defect at age 5
months, which was complicated by complete heart block
requiring placement of an epicardial dual-chamber pace-
maker 5 days after the repair, and pulmonary valve replace-
ment at age 18 months, placement of a new epicardial
pacing system was not recommended by the cardiac surgery
team. The patient was referred for a transvenous pacing
system. After discussion with the referring cardiologist and
the patient’s parents, and after careful consideration of the
risks of lifelong transvenous pacing compared to the risks
of a large-bore (23F) delivery sheath in the femoral vein,
possible cardiac perforation and/or pericardial effusion, and
the many potential unknown or unreported risks of leadless
pacing (eg, multiple abandoned devices within the ventricle,
possible need for surgical retrieval or extraction), transcath-
eter leadless pacing (Micra Transcatheter Pacing System,
Medtronic, Minneapolis, MN) was offered to the patient.
While under general anesthesia, the patient underwent a
diagnostic right and left heart catheterization to confirm
normal hemodynamics, minimal stenosis of the RV-PA
conduit, and normal PA pressures. She then underwent elec-
trophysiological study to confirm the absence of sustained
ventricular arrhythmias and supraventricular tachycardia.
After a right femoral venogram was performed to rule out
significant stenosis of the common femoral vein, iliac vein,
and inferior vena cava, serial dilations of the right femoral
vein were performed with 12F, 16F, 18F, 20F, and 22F hy-
drophilic dilators. The proprietary 23F sheath was then
placed over a wire and advanced to the middle of the right
atrium. The delivery catheter was advanced through the
sheath, and the sheath was withdrawn into the inferior venaen access article
.0/).
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KEY TEACHING POINTS
 Postoperative atrioventricular (AV) nodal injury
frequently necessitates lifelong backup pacing in
patients with repaired congenital heart disease
because of the unpredictability of late recurrence of
AV nodal block.
 Permanent pacing in pediatric and congenital heart
disease patients requires careful consideration of the
cumulative risks of pacemaker implant techniques
over the entire course of the patient’s life.
 Leadless pacing via a transcatheter pacing system is
feasible in pediatric patients with repaired
congenital heart disease and minimizes the lifelong
burden of pacing by eliminating lead-related
complications.
Figure 1 Leadless pacemaker implant final position. Biplane fluoroscopy
of leadless pacemaker in the right ventricle with fractured atrial and ventric-
ular epicardial leads, surgical clips, and sternal wires. The intracardiac echo-
cardiogram catheter is seen in the right atrium advanced through the
proprietary 23F delivery sheath from the right femoral venous approach.
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was deflected across the tricuspid valve into the RV. Contrast
injection through the catheter under biplane fluoroscopy
confirmed the septal and apical location of the catheter.
The pacing system was exposed from the catheter and im-
planted onto the RV septum. The catheter was withdrawn,
and control was maintained on the pacemaker using the su-
ture adhered to the distal ring. Initial implant parameters
were suboptimal, with pacing threshold .2.0 V at 0.24 ms,
sensed R waves ,5 mV, and pacing impedance ,500 U.
The pacing system was recaptured with the delivery catheter,
and the delivery system was repositioned. Again, suboptimal
implant parameters were achieved, and the device was recap-
tured and repositioned. Ultimately, the device required repo-
sitioning 7 times before acceptable implant parameters were
achieved: pacing threshold of 1.25 V at 0.24 ms, sensed R
wave of 4.4 mV, and pacing impedance of 480 U. The deliv-
ery sheath was removed, and intracardiac echocardiography
was used to visualize the pacing system in the RV
(Figure 1). The delivery sheath was removed, and hemostasis
was maintained with 2 vascular closure devices (PerClose
Proglide, Abbott Vascular, Abbott Park, IL) placed with
the assistance of interventional cardiology. The existing
pacemaker generator in the right upper abdomen was
removed, and the epicardial leads were capped with the assis-
tance of cardiothoracic surgery.
The patient was admitted overnight. A pacemaker interro-
gation performed the following day revealed a mild increase
in pacing threshold to 2.6 V at 0.24 ms and 2.0 V at 0.4 ms,
with mild decrease in R-wave sensing to 4.2 mV but stable
pacing impedance of 480 U. Chest radiograph and transtho-
racic echocardiogram confirmed stable device position. After
discussion with the device manufacturer, the decision was
made to not reposition the device but to follow the threshold
closely on an outpatient basis, and the patient was discharged
home.The pacing threshold continued to rise during outpatient
follow-up, reaching a maximum pacing threshold of 3.25 V
at 0.24 ms 2 weeks after implant despite stable appearance
on chest radiograph, and stable R-wave sensing and imped-
ance. Over the next 10 weeks, the pacing threshold steadily
decreased. Three months after implant, the pacing threshold
was 2.0 V at 0.24 ms, with R-wave sensing of 6.0 mV and
pacing impedance of 490 U. At 9-month follow-up, pacing
parameters remain stable, and the patient is paced approxi-
mately 1% of the time.Discussion
Leadless transcatheter pacing systems have been studied
extensively in adults with structurally normal hearts in both
Europe and the United States.6,7 These systems have
demonstrated low complication rates at both implantation
and throughout short- to mid-term follow-up.8,9 However,
implantation of a leadless transcatheter pacing system in a
Figure 2 Biplane right ventriculogram showing heavily trabeculated right
ventricle with right ventricle to pulmonary artery conduit extending from the
mid-anterior right ventricle.
Figure 3 Postimplant intracardiac echocardiogram showing the leadless
pacemaker in an apical location inferior to the takeoff of the right ventricle
to pulmonary artery conduit.
508 Heart Rhythm Case Reports, Vol 4, No 11, November 2018pediatric patient or a patient with significant CHD had not
previously been described before this case of implantation
of the Micra Transcatheter Pacing System in a 12-year-old
girl with tetralogy of Fallot.
The decision to implant this device rather than a transve-
nous pacing system or an epicardial pacing system was based
on long-term complications. Because the life expectancy of
patients with tetralogy of Fallot and other significant CHDs
continues to increase, approaching that of people without
CHD, the expectation of lifelong pacing in such individuals
means that our 12-year-old patient potentially could require
rare, intermittent pacing for 60–70 years. Thus, considering
the lifelong complications of pacing becomes crucial to ex-
tending the patient’s lifespan.Pacing in pediatric patients and patients with CHD is asso-
ciated with higher complication rates than pacing in adults
with structurally normal hearts.10,11 Lead-related complica-
tions remain the most significant, with lead failure rates as
high as 15% over mid- to long-term follow-up.1 Venous
thrombosis and endovascular infection are other long-term
risks of transvenous pacing systems. Even in ideal situations
without immediate complications, lead performance deterio-
rates over time. Therefore, a young patient with transvenous
leads is likely to experience deterioration in lead performance
and possibly lead failure at some point over the life course,
and the physician caring for the patient must decide between
lead extraction and abandonment.12 The rate of major com-
plications from lead extraction procedures, including major
vascular injury, remains high in pediatric and CHD pa-
tients.13 By eliminating the primary instrument of complica-
tions, leadless pacemakers are well suited to meet the pacing
demands of many pediatric patients with CHD who require
intermittent pacing because of surgically created conduction
system disease.
As part of the preprocedural discussion with the family
and informed consent to perform this procedure for the first
time at our institution, we acknowledged that data on the
long-term performance of the device and its potential long-
term complications are lacking compared to traditional
approaches, and that complications may present that have
not previously been described. We also discussed future pac-
ing strategies for the patient, which may include transvenous
pacing to provide DDD pacing or cardiac resynchronization
therapy if the patient were to develop indications for either
treatment. Regarding the abandonment of this leadless pace-
maker and/or multiple leadless systems in the RV, we dis-
cussed with our patient that she is likely to require at least
1 other cardiac surgery for RV-PA conduit replacement in
adolescence or young adulthood before transvenous pulmo-
nary valve replacement, at which time the abandoned
device(s) could be retrieved by a cardiothoracic surgeon.
Regarding the implant technique, an RV angiogram per-
formed before implantation as part of planning the cardiac
catheterization was helpful in determining the true
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echocardiography, which was used as part of the electrophys-
iological study, was helpful in evaluating the position of the
device in relation to the takeoff of the RV-PA conduit
(Figure 3).
Many of the sites sampled within the RV had suboptimal
lead parameters despite multiple deployments. Similarly, the
parameters worsened over the first several weeks before they
stabilized. However, knowing that improvement in subopti-
mal pacing thresholds in patients with the Micra system
had been studied and described, our implant was not reposi-
tioned after the initial procedure. Fortunately, our experience
is similar to that of Piccini and colleagues,14 showing
improvement of the threshold by 1 month and 6 months.
Although the exact cause of the suboptimal parameters is
not known, the patient had undergone cardiopulmonary
bypass 3 times during her staged repair of tetralogy of Fallot,
all of which had the potential for endocardial ischemia. RV
hypertrophy with thick trabeculations defines tetralogy of
Fallot, and contact of the distal electrode may have been
altered by its positioning within trabeculations. Fortunately,
the parameters returned to an acceptable range, and the de-
vice did not need to be retrieved or repositioned.Conclusion
This case demonstrates the feasibility of implanting a leadless
pacemaker in a 12-year-old, 37-kg patient with tetralogy of
Fallot. To our knowledge, this is among the first transcatheter
pacemaker implants reported in a pediatric patient with sig-
nificant CHD. Despite challenges in finding an optimal
implant site possibly because of factors specific to repaired
tetralogy of Fallot, such as a history of endocardial ischemia
from bypass and thick trabeculations of the RV, the implant
was successful, without procedural complications and with
adequate pacing parameters. By eliminating the lead-related
complications of endovascular pacing, leadless pacing offersan excellent option for young patients with CHD in need of
lifelong pacing.References
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